Medical outcomes and antimicrobial compliance according to the Chilean Society of Respiratory Diseases guidelines for hospitalized patients with community acquired pneumonia;Utilidad clínica del tratamiento antibiótico de la guía de la Sociedad Chilena de Enfermedades Respiratorias para la neumonía comunitaria en adultos hospitalizados

Revista Medica de Chile

Volumn 131, Issue 8, 2003, Pages 847-856

  Díaz F, Alejandro ^a   Kuzmanic G, Gabriela ^a   Platzer M, Liesbeth ^a   Sanfuentes P, Francisca ^a   Espinoza S, Manuel A ^a   Saldías P, Fernando ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Antibiotics; Guideline adherence; Pneumonia, bacterial; Respiratory therapy

Indexed keywords

ANTIBIOTIC AGENT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTIBIOTIC THERAPY; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DATA ANALYSIS; DISEASE SEVERITY; FEMALE; HIGH RISK PATIENT; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; IMMUNOCOMPETENCE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; PRACTICE GUIDELINE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHILE; COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; GUIDELINE ADHERENCE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PNEUMONIA, BACTERIAL; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 12444301736     PISSN: 00349887     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. VALDIVIA G. Neumonías adquiridas en la comunidad: epidemiología y conceptos generales. Bol Esc Med Universidad Católica 1999; 28: 85-91.
2. NIEDERMAN MS, BASS JB JR, CAMPBELL GD, FEIN A, GROSSMAN R, MANDELL L ET AL. Guidelines for the initial management of adults with community acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. Am Rev Respir Dis 1993; 148: 1418-26.
3. SALDÍAS F, MARDÓNEZ J, MARCHESSE M, VIVIANI P, FARÍAS G, DÍAZ A. Neumonía adquirida en la comunidad en el adulto hospitalizado. Cuadro clínico y factores pronósticos. Rev Méd Chile 2002; 130: 1373-82.
4. SALDÍAS F, O'BRIEN A, GEDERLINI A, FARÍAS G, DÍAZ A. Neumonía adquirida en la comunidad en el anciano inmunocompetente que requiere hospitalización. Cuadro clínico, factores pronósticos y tratamiento. Arch Bronconeumol 2003; 39: 333-40.
5. DÍAZ A, CALVO M, O'BRIEN A, FARÍAS G, MARDÓNEZ J, SALDÍAS F. Utilidad clínica de los hemocultivos en pacientes hospitalizados por neumonía adquirida en la comunidad. Rev Méd Chile 2002; 130: 993-1000.
6. DORCA J, BELLO S, BLANQUER J ET AL. Diagnóstico y tratamiento de la neumonía adquirida en la comunidad. Arch Bronconeumol 1997; 33: 240-6.
7. BARTLETT JG, DOWELL SF, MANDELL LA, FILE JR TM, MUSHER DM, FINE MJ. Practice guidelines for the management of community acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000; 31: 347-82.
8. SOCIEDAD CHILENA DE ENFERMEDADES RESPIRATORIAS. Consenso Nacional en Neumonías del Adulto Adquiridas en la Comunidad. Rev Chil Enf Respir 1999; 15: 70-105.
9. FEIN AM, NIEDERMAN MS. Guidelines for the initial management of community acquired pneumonia: savory recipe or cookbook for disaster? Am J Respir Crit Care Med 1995; 152: 1149-53.
10. WOODHEAD M. Community acquired pneumonia guidelines: much guidance, but not much evidence. Eur Respir J 2002; 20: 1-3.
11. HIRANI NA, MACFARLANE JT. Impact of management guidelines on the outcome of severe community acquired pneumonia. Thorax 1997; 52: 17-21.
12. GLEASON PP, KAPOOR WN, STONE RA, LAVE JR, OBROSKY S, SCHULZ R ET AL. Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community acquired pneumonia. JAMA 1997; 278: 32-9.
13. MARRIE TJ, LAU CY, WHEELER SL, WONG CJ, VANDERVOORT MK, FEAGAN BG. A controlled trial of a critical pathway for treatment of community acquired pneumonia. CAPITAL Study Investigators. Community Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA 2000; 283: 749-55.
14. MALONE DC, SHABAN HM. Adherence to ATS guidelines for hospitalized patients with community acquired pneumonia. Ann Pharmacother 2001; 35: 1180-5.
15. MENÉNDEZ R, FERRANDO D, VALLES JM, VALLTERRA J. Influence of deviation from guidelines on the outcome of community acquired pneumonia. Chest 2002; 122: 612-7.
16. MARRAS TK, CHAN CK. Use of guidelines in treating community acquired pneumonia. Chest 1998; 113: 1689-94.
17. FANG GD, FINE M, ORLOFF J, ARISUMI D, YU VL, KAPOOR W ET AL. New and emerging etiologies for community acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases. Medicine (Baltimore) 1990; 69: 307-16.
18. FINE MJ, AUBLE TE, YEALY DM, HANUSA BH, WEISSFELD LA, SINGER DE ET AL. A prediction rule to identify low risk patients with community acquired pneumonia. N Engl J Med 1997; 336: 243-50.
19. DOWELL SF, SMITH T, LEVERSEDGE K, SNITZER J. Failure of treatment of pneumonia associated with highly resistant pneumococci in a child. Clin Infect Dis 1999; 29: 462-3.
20. AMERICAN COLLEGE OF CHEST PHYSICIANS/SOCIETY OF CRITICAL CARE MEDICINE. Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-74.
21. WEINGARTEN SR, RIEDINGER MS, HOBSON P, NOAH M, JOHNSON B, GIUGLIANO G ET AL. Evaluation of a pneumonia practice guideline in an interventional trial. Am J Respir Crit Care Med 1996; 153: 1110-5.
22. PERRY CM, BROGDEN RN. Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1996; 52: 125-58.
23. HIGUERA F, HIDALGO H, FERIS J, GIGUERE G, COLLINS JJ. Comparison of oral cefuroxime axetil and oral amoxycillin/clavulanate in the treatment of community acquired pneumonia. J Antimicrob Chemother 1996; 37: 555-64.
24. VAN DEN BRANDE P, VONDRA V, VOGEL F, SCHLAEFFER F, STALEY H, HOLMES C. Sequential therapy with cefuroxime followed by cefuroxime axetil in community acquired pneumonia. Chest 1997; 112: 406-15.
25. SÁNCHEZ ME, GÓMEZ J, GÓMEZ VARGAS J, BAÑOS V, RUIZ GÓMEZ J, MUÑOZ L ET AL. Prospective and comparative study between cefuroxime, ceftriaxone and amoxicillin-clavulanic acid in the treatment of community acquired pneumonia. Rev Esp Quimioter 1998; 11: 132-8.
26. NIEDERMAN MS, MANDELL LA, ANZUETO A, BASS JB, BROUGTHON WA, CAMPBELL GD ET AL. Guidelines for the management of adults with community acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention. Am J Respir Crit Care Med 2001; 103: 1730-54.
27. MARIK PE. Aspiration pneumonitis and aspiration pneumonia. N Engl J Med 2001; 344: 665-71.
28. RIQUELME R, TORRES A, EL-EBIARY M, DE LA BELLACASA JP, ESTRUCH R, MENSA J ET AL. Community acquired pneumonia in the elderly: A multivariate analysis of risk and prognostic factors. Am J Respir Crit Care Med 1996; 154: 1450-5.
29. DÍAZ FUENZALIDA A, VERA C, SANTAMARINA J, IZARDUY L, BAGNASCO R, GRINSPON S ET AL. Neumonía adquirida en la comunidad en ancianos que requieren internación. Cuadro clínico y pronóstico. Medicina (B Aires) 1999; 59: 731-8.
30. WEINGARTEN S, RIEDINGER MS, SANDHU M, BOWERS C, ELLRODT AG, NUNN C ET AL. Can practice guidelines safely reduce hospital length of stay? Results from a multicenter interventional study. Am J Med 1998; 105: 33-40.
31. FINE MJ, SINGER DE, PHELPS AL, HANUSA BH, KAPOOR WN. Differences in length of hospital stay in patients with community acquired pneumonia: a prospective four hospital study. Med Care 1993; 31: 371-80.
32. MENÉNDEZ R, FERRANDO D, VALLES JM, MARTÍNEZ E, PERPINA M. Initial risk class and length of hospital stay in community acquired pneumonia. Eur Respir J 2001; 18: 151-6.